Episode 301: 300. A New Trial On Beta Blockers and COPD

Episode 301: 300. A New Trial On Beta Blockers and COPD

The problems with observation data is real—

randomized trial, U.K. researchers identified 519 patients (mean age, 68) with mostly moderate COPD (mean forced expiratory volume in 1 second [FEV1], 50%), ≥2 exacerbations during the previous year, and no cardiovascular (CV) indications for β-blockers.

Patients were randomized to receive the cardioselective β-blocker bisoprolol (initially 1.25 mg daily, titrated to 5 mg if tolerated) or placebo.

At 1 year, no significant differences were noted between groups in incidence of COPD exacerbations or in other important benefits or harms.



Cardioselective β-blockers remain appropriate for COPD patients who have valid cardiovascular indications for their use, but taken these two studies together suggests that COPD patients without such indications should avoid bblockers—even cardio selective beta blockers

https://jamanetwork.com/journals/jama/article-abstract/2819083

Jaksot(385)

Episode 375: 386. Could half dose anticoagulation be the answer?

Episode 375: 386. Could half dose anticoagulation be the answer?

Estimated 5-year incidence of recurrent VTE was similar in the reduced-dose and full-dose groups (2.2% and 1.8%). Estimated 5-year bleeding incidence was significantly lower with reduced-dose than wi...

14 Maalis 20258min

Episode 374: 385. PRACTICE CHANGER! Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

Episode 374: 385. PRACTICE CHANGER! Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

https://www.nejm.org/doi/full/10.1056/NEJMoa2405404NNT of 4! systemic metronid and topical clinda bid for one week

12 Maalis 20256min

Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect

Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect

What Was Studied?The EMPA-KIDNEY trial followed 6,609 CKD patients at risk of disease progression. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo for a median ...

11 Maalis 20259min

Episode 372: 383. What is the GFR at which we stop metforin?

Episode 372: 383. What is the GFR at which we stop metforin?

Metformin while not necessarily first line therapy for diabetes depending on the patients co-morbid conditions it is certainly highly ranked on the list of medications! I know often metformin is stopp...

6 Maalis 202510min

Episode 371: 382. Is it safe to give the flu and covid vaccine at the same time?

Episode 371: 382. Is it safe to give the flu and covid vaccine at the same time?

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2825813Conclusions and Relevance  In this randomized clinical trial assessing simultaneous vs sequential administration of mRNA COVID-19 an...

4 Maalis 20257min

Episode 370: 381. Relative efficacy of prehabilitation interventions and their components

Episode 370: 381. Relative efficacy of prehabilitation interventions and their components

https://www.bmj.com/content/388/bmj-2024-081164systematic review and meta-analysis on prehabilitation before surgery, published in the BMJ in February 2025.Prehabilitation aims to prepare patients for...

27 Helmi 20257min

Episode 369: 380. REPOST mammo part 2

Episode 369: 380. REPOST mammo part 2

Mammograms

24 Helmi 202520min

Episode 368: 379. REPOST mammogram part 1

Episode 368: 379. REPOST mammogram part 1

379. REPORT mammogram part 1

18 Helmi 202519min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
rss-pitaisko-erota
vakeva-elama-viisaampi-mieli-vahvempi-keho
meditaatiot-suomeksi
junnut-pelissa
rss-mighty-finland-podcast
puhu-muru
rss-narsisti
terapiassa
paritellen
aamukahvilla
mielen-puolikkaat
rss-uplevel-by-sonja-hannus
rss-pt-paahtio
rss-vapaudu-voimaasi
rss-adama-mindful-hetki
rss-nautinto